EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer

Yong-Li Gu, Zeng-Xian Sun, Ying Sun, Xin Guan, Dao-Li Jiang

Int. Journal of Clinical Pharmacology and Therapeutics · 2024

DOI: 10.5414/cp204479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Yong-Li Gu und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutropenia, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeutropeniaAntineoplastic AgentsPolyethylene GlycolsHumansCost-Effectiveness AnalysisGranulocyte Colony-Stimulating FactorRecombinant ProteinsGranulocytesAntineoplastic Combined Chemotherapy Protocols

Substanzen

pegylated granulocyte colony-stimulating factorGranulocyte Colony-Stimulating FactorRecombinant ProteinsAntineoplastic AgentsPolyethylene Glycols

Zitieren

APA

Gu, Y. L., Sun, Z. X., Sun, Y., Guan, X., & Jiang, D. L. (2024). Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204479

Vancouver

Gu YL, Sun ZX, Sun Y, Guan X, Jiang DL. Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204479

BibTeX
@article{Gu2024,
  author = {Gu, Yong-Li and Sun, Zeng-Xian and Sun, Ying and Guan, Xin and Jiang, Dao-Li},
  title = {Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2024},
  doi = {10.5414/cp204479}
}
Kostenlos starten →